Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

CD19/CD22 bispecific CAR-t cell therapy for relapsed/refractory large b-cell lymphoma: A prospective, single-arm, single-center, phase 2 clinical trial

View Full Paper
Ask AI
Bookmark
Share

Authors

YLYong LiangJCJia CongLWLiang Wang

Discussion

Loading...

Member takes

Overview

Phase 2 trial reports 100% response rate after CD19/CD22 CAR-T cell therapy in R/R LBCL patients, highlighting potential benefits and safety.

Key Points

  • Best overall response rate reached 100% in patients treated with CD19/CD22 bispecific CAR-T therapy.
  • Adverse events included neutropenia (93.5%), thrombocytopenia (77%), and cytokine release syndrome (74%).
  • Efficacy metrics such as progression-free survival and overall survival are still being evaluated.
  • This approach shows promise in enhancing treatment options for patients with relapsed/refractory large B-cell lymphoma.

Cite This Study

Liang et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d931https://doi.org/10.1182/blood-2025-570
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety and efficacy of CD19/CD22/CD20 multi-targeted CAR-T therapy in patients with refractory/relapsed B-cell non-Hodgkin lymphoma2025
  2. 2Updated clinical outcomes of a Phase I/II trial of bispecific CD19/CD20-targeted CAR-T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma2025
  3. 3Sequential CD19/CD22 CAR-T cell therapy following ASCT shows improved efficacy versus CAR-t alone in relapsed/refractory large B-cell lymphoma2025
  4. 4Sequential CD19 and CD22 CART for relapsed and refractory B cell ALL: Phase I results2025
  5. 5Long-term outcomes of CNCT19 chimeric antigen receptor T-cell therapy in relapsed or refractory aggressive B-cell lymphoma2025